Cargando…

Outcomes With Belatacept Exposure During Pregnancy in Kidney Transplant Recipients: A Case Series

BACKGROUND. Posttransplant fertility returns quickly, and female recipients of child-bearing age may conceive while on immunosuppression. However, pregnancy after transplantation confers risks to the recipient, transplant, and fetus, including gestational hypertension, preeclampsia, gestational diab...

Descripción completa

Detalles Bibliográficos
Autores principales: Coscia, Lisa, Cohen, David, Dube, Geoffrey K., Hofmann, R. Michael, Moritz, Michael J., Gattis, Sara, Basu, Arpita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442140/
https://www.ncbi.nlm.nih.gov/pubmed/37287109
http://dx.doi.org/10.1097/TP.0000000000004634
_version_ 1785093524864106496
author Coscia, Lisa
Cohen, David
Dube, Geoffrey K.
Hofmann, R. Michael
Moritz, Michael J.
Gattis, Sara
Basu, Arpita
author_facet Coscia, Lisa
Cohen, David
Dube, Geoffrey K.
Hofmann, R. Michael
Moritz, Michael J.
Gattis, Sara
Basu, Arpita
author_sort Coscia, Lisa
collection PubMed
description BACKGROUND. Posttransplant fertility returns quickly, and female recipients of child-bearing age may conceive while on immunosuppression. However, pregnancy after transplantation confers risks to the recipient, transplant, and fetus, including gestational hypertension, preeclampsia, gestational diabetes, transplant dysfunction, preterm labor, and low birthweight infants. Additionally, mycophenolic acid (MPA) products are teratogenic. Literature evidence regarding belatacept, a selective T-cell costimulation blocker, during pregnancy and while breastfeeding is extremely limited. When female transplant recipients on a belatacept-based regimen are desirous of pregnancy or at the time of conception, transplant providers manage the immunosuppression regimen in 1 of 2 ways: (1) switch both belatacept and MPA to a calcineurin inhibitor–based regimen with or without azathioprine, which is the more common practice but requires several modifications, having potential negative outcomes; or (2) only switch MPA to azathioprine while continuing belatacept. METHODS. This case series includes 16 pregnancies in 12 recipients with exposure to belatacept throughout pregnancy and while breastfeeding. Patient information was obtained from several sources, including Transplant Pregnancy Registry International, providers at Emory University, and Columbia University, as well as literature review. RESULTS. Pregnancy outcomes included 13 live births and 3 miscarriages. No birth defects or fetal deaths were reported in any of the live births. Seven infants were breastfed while their mothers continued belatacept. Outcomes appear comparable to those documented with the administration of calcineurin inhibitors. CONCLUSIONS. This case series provides data supporting the continued administration of belatacept during pregnancy. Additional research will assist in developing better guidelines to counsel female transplant recipients on belatacept desiring to pursue pregnancy.
format Online
Article
Text
id pubmed-10442140
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104421402023-08-22 Outcomes With Belatacept Exposure During Pregnancy in Kidney Transplant Recipients: A Case Series Coscia, Lisa Cohen, David Dube, Geoffrey K. Hofmann, R. Michael Moritz, Michael J. Gattis, Sara Basu, Arpita Transplantation Original Clinical Science—General BACKGROUND. Posttransplant fertility returns quickly, and female recipients of child-bearing age may conceive while on immunosuppression. However, pregnancy after transplantation confers risks to the recipient, transplant, and fetus, including gestational hypertension, preeclampsia, gestational diabetes, transplant dysfunction, preterm labor, and low birthweight infants. Additionally, mycophenolic acid (MPA) products are teratogenic. Literature evidence regarding belatacept, a selective T-cell costimulation blocker, during pregnancy and while breastfeeding is extremely limited. When female transplant recipients on a belatacept-based regimen are desirous of pregnancy or at the time of conception, transplant providers manage the immunosuppression regimen in 1 of 2 ways: (1) switch both belatacept and MPA to a calcineurin inhibitor–based regimen with or without azathioprine, which is the more common practice but requires several modifications, having potential negative outcomes; or (2) only switch MPA to azathioprine while continuing belatacept. METHODS. This case series includes 16 pregnancies in 12 recipients with exposure to belatacept throughout pregnancy and while breastfeeding. Patient information was obtained from several sources, including Transplant Pregnancy Registry International, providers at Emory University, and Columbia University, as well as literature review. RESULTS. Pregnancy outcomes included 13 live births and 3 miscarriages. No birth defects or fetal deaths were reported in any of the live births. Seven infants were breastfed while their mothers continued belatacept. Outcomes appear comparable to those documented with the administration of calcineurin inhibitors. CONCLUSIONS. This case series provides data supporting the continued administration of belatacept during pregnancy. Additional research will assist in developing better guidelines to counsel female transplant recipients on belatacept desiring to pursue pregnancy. Lippincott Williams & Wilkins 2023-06-08 2023-09 /pmc/articles/PMC10442140/ /pubmed/37287109 http://dx.doi.org/10.1097/TP.0000000000004634 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Original Clinical Science—General
Coscia, Lisa
Cohen, David
Dube, Geoffrey K.
Hofmann, R. Michael
Moritz, Michael J.
Gattis, Sara
Basu, Arpita
Outcomes With Belatacept Exposure During Pregnancy in Kidney Transplant Recipients: A Case Series
title Outcomes With Belatacept Exposure During Pregnancy in Kidney Transplant Recipients: A Case Series
title_full Outcomes With Belatacept Exposure During Pregnancy in Kidney Transplant Recipients: A Case Series
title_fullStr Outcomes With Belatacept Exposure During Pregnancy in Kidney Transplant Recipients: A Case Series
title_full_unstemmed Outcomes With Belatacept Exposure During Pregnancy in Kidney Transplant Recipients: A Case Series
title_short Outcomes With Belatacept Exposure During Pregnancy in Kidney Transplant Recipients: A Case Series
title_sort outcomes with belatacept exposure during pregnancy in kidney transplant recipients: a case series
topic Original Clinical Science—General
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442140/
https://www.ncbi.nlm.nih.gov/pubmed/37287109
http://dx.doi.org/10.1097/TP.0000000000004634
work_keys_str_mv AT coscialisa outcomeswithbelataceptexposureduringpregnancyinkidneytransplantrecipientsacaseseries
AT cohendavid outcomeswithbelataceptexposureduringpregnancyinkidneytransplantrecipientsacaseseries
AT dubegeoffreyk outcomeswithbelataceptexposureduringpregnancyinkidneytransplantrecipientsacaseseries
AT hofmannrmichael outcomeswithbelataceptexposureduringpregnancyinkidneytransplantrecipientsacaseseries
AT moritzmichaelj outcomeswithbelataceptexposureduringpregnancyinkidneytransplantrecipientsacaseseries
AT gattissara outcomeswithbelataceptexposureduringpregnancyinkidneytransplantrecipientsacaseseries
AT basuarpita outcomeswithbelataceptexposureduringpregnancyinkidneytransplantrecipientsacaseseries